They suggest that detailed recognition of a history of infection, including circumstances of virus acquisition, longevity of chronic hepatitis, the host’s global T cell immune responses, and properties of the antibodies used might be required to predict with greater confidence consequences of the PD-1/PD-L1 blockage in a given individual or animal. Here, PDCD1 is linked to chronic hepatitis.